"WOO" Windows of Opportunity

[humblehawk]

HNAB @ .20 alert: RECOVERY PLAY

http://stockcharts.com/h-sc/ui?s=hnab&p=D&yr=0&mn=6&dy=0&id=p24126473379


CHART IS GETTING BETTER. Will keep going. Great recovery play here...more bull flags on the issue.

THINK HNAB gets back to AT LEAST .35...but looks like .40 -.60 is doable...and perhaps if there is a change and NEWS that is positively correcting...could see $1+

FYI:
HGSI dropped big time before it went up

HGSI hit a low of .45 before becoming the $30 stock it is today

http://stockcharts.com/h-sc/ui?s=HGSI&p=D&yr=3&mn=0&dy=0&id=p15815640292

A doesnt always = B, but you never know.

STOCKS
showing SUPPORT over their 200 day moving average

*timing is key when executing your trading plan!

**Check out their pipeline and more:
http://files.shareholder.com/downloads/HNAB/819881047x0x234717/40046CB8-6148-43F6-87AC-D3194C86932C/HNAB_081408.pdf

Market cap of about $14.77 M; perhaps it makes them a nice takeover target?

Hana Biosciences, Inc. (Hana) is a biopharmaceutical company is engaged in acquiring, developing and commercializing products to strengthen the foundation of cancer care. The Company’s two lead product candidates are in pivotal and/or proof-of-concept clinical trials. The Company is developing Marqibo for the treatment of acute lymphoblastic leukemia (ALL) and lymphomas. Menadione topical lotion is a compound that it is developing for the potential prevention and/or treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. Its product candidates in various stages of development include Marqibo, Menadione Topical Lotion, Brakiva and Alocrest.

Recent key development(s):

*Hana Biosciences reports positive results from Phase II leukemia trial


http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=HNAB.OB×tamp=20091008233300